TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of 2 to 6 migraine headaches per month~* Migraines should have been present for at least 1 year with age at onset of migraine less than 50 years~* History of 24 hours of freedom between migraine attacks~* Current users of triptan medications~* Able to distinguish interval or other non-migrainous headaches from typical migraine~* General good health~Exclusion Criteria:~* History or symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes~* Significant underlying cardiovascular diseases including uncontrolled hypertension~* Hemiplegic or basilar migraine~* History or diagnosis of severe hepatic or renal impairment~* History of epilepsy or seizure or other serious neurologic condition~* History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or any of its components or similar drugs including sulphonamides~* History of scleroderma (systemic sclerosis)~* Pregnant or breastfeeding~* Use of contraindicated prescription medications, monoamine oxidase inhibitors (MAO-A), selective serotonin reuptake inhibitors, or lithium agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sumavel(R) DosePro(R) (Type: OTHER): Single arm study (Sumavel DosePro)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Theophylline for Low Adenosine Syncope

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female gender with age \>18 years~2. Unexplained syncope without prodrome or neurally-mediated syncope with atypical prodrome, with normal heart and normal ECG~3. Two syncopes /last year or 3 syncopes /last 2 years before start of theophylline treatment~4. Having received an ICM according to conventional guideline-based indications~5. Being treated with oral theophylline therapy, while been waiting for ICM diagnosis~6. Having signed a written informed consent to the study participation and to the treatment of personal data~Exclusion Criteria:~1. Typical vaso-vagal syncope with long prodromes and situational syncope~2. Any other form of syncope/T-LOC different from reflex syncope~3. Pregnant or breast-feeding patients -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Theophylline group (Type: None): Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
- Control untreated group (Type: None): A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18, under 75 years of age~* Patients with non-alcoholic fatty liver disease~Exclusion Criteria:~* Over 2 ratio of AST to ALT~* Type 1 diabetes mellitus (insulin-dependent diabetes mellitus)~* Disorder in liver function with an exception of non-alcoholic fatty liver (e.g. Virus infection, biliary atresia, autoimmune hepatitis and etc.)~* Patients who have been taken drugs induced fatty liver for over 3 month within 1 year of participation in this study; amiodarone, tamoxifen, methotrexate, tetracyclines, glucocorticoids, anabolic steroids, over usual dose of estrogen for hormone replacement therapy and valproate~* Patients who has been taken any medications that could affect the treatment for non-alcoholic steatohepatitis: insulin, insulin sensitizer(metformin, thiazolidinedione), high dose of vitamin E, high dose of UDCA, pentoxifylline, SAM-e, Betaine, types of Statin, types of fibrate and orlistat~* Patients who had a Bariatric surgery less than 6 month prior to the participation in the study~* Patients who are judged by investigator that participation of the study is difficult due to disease as follow; hepatic cirrhosis, Wilson's disease, malignant tumor, serious metabolic disease, severe renal disease, severe pulmonary disease, severe cardiovascular disease, severe nervous disease/psychiatric disorder, muscle disease and etc~* Any history of immune disorder which affect the changes in cytokine:~inflammatory bowel disease, autoimmune thrombocytopenic purpura, system lupus erythematosus, autoimmune hemolytic anemia, severe psoriasis, rheumatic arthritis and etc~* Patients who have received treatment that may affect liver function within 1 month prior to the participation in the study~* Patient who has been administered other investigational product within 1 month prior to the participation in the study~* Patient who is not allowed to get MRS test: pacemaker, shunt and etc~* Pregnant or nursing women~* Patient who considered ineligible for participation in the study as Investigator's judgment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Oltipraz (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes \> 5 years~* One or more episodes of nocturnal severe hypoglycaemia during the preceding two years~* Treated with multiple dose insulin injection (\>2) or insulin pump. Both human insulin and insulin analogues are allowed~* Willingness to a once daily (OD) regimen concerning insulin degludec and insulin glargine~* Willingness to do self-monitoring of blood glucose (SMBG) and keep a diary~* Signed informed consent~Exclusion Criteria:~* History of primary and secondary adrenal insufficiency, growth hormone deficiency, or untreated myxoedema~* History of unstable angina or major cardiovascular events (myocardial infarction, coronary re-vascularisation, transient ischaemic attack, or stroke within the last three months)~* Heart failure, New York Heart Association (NYHA) class IV~* History of malignancy unless a disease-free period exceeding five years~* History of alcohol or drug abuse~* Treatment with glucose lowering agent(s) other than insulin~* Pregnant or lactating women~* Women of childbearing potential who are not using chemical (P-pills or gestagen depots) or mechanical (intra-uterine device) contraception~* Participation in another investigational drug study within the last 3 months~* Inability to understand the informed consent~* HbA1c \> 86 mmol/mol (10%)~* Shifting working hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals.
- Insulin degludec (Type: EXPERIMENTAL): Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 18 years of age and older~* Patients who are eligible and able to participate in the study~Exclusion Criteria:~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of hypertensive encephalopathy or cerebrovascular accident.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subunit Vaccine Against Herpes Zoster in RA Patients Treated With JAK-inhibitors (VACCIMIL-ZOSTER)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~age\>18 years RA diagnosis RA patients treated with JAK-inhibitors as monotherapy or in combination with MTX and/or other DMARDs/prednisolone for at least 3 months (group1) regulary follow up at the rheumatology departmenet~Exclusion Criteria:~* pregnancy~* breastfeeding~* allergi against some of compnents in the vaccine~* ongoing infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RA patients on JAK inhibitors (Type: ACTIVE_COMPARATOR): RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDs/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
- healthy controls (Type: ACTIVE_COMPARATOR): healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of RA and requiring Tocilizumab therapy~* Subject has provided written informed consent~Exclusion Criteria:~* Corticosteroid therapy (10 mg/day of prednisone or equivalent)~* Pregnant or lactating women~* Uncontrolled type 1 or type 2 diabetes~* Uncontrolled dyslipidemia~* Elevated transaminases (\> three times higher than the normal range)~* History of diverticulitis or intestinal perforation~* Tocilizumab contraindications: Severe or active infections, Hypersensitivity to the active substance or to any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Adiponectin evaluation (Type: EXPERIMENTAL): Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patients with essential hypertension~* Patients who are eligible and able to participate in the study~Exclusion Criteria~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of Hypertensive encephalopathy or cerebrovascular accident~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Participants who met the following criteria were eligible to participate in this study.~Inclusion Criteria:~* Advanced ovarian epithelial cancer, treated with paracentesis~* Platinum-resistant, and topotecan-resistant and/or liposomal doxorubicin-resistant disease;~* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2.~Exclusion Criteria:~* Pseudomyxoma peritonei or peritoneal mesothelioma;~* Transudative ascites;~* Peritoneovenous or other shunt placed for malignant ascites management;~* Recent (\<6 months) cardiovascular event (pulmonary embolus, myocardial infarction, stroke) or gastrointestinal disease (ulcer, hepatic cirrhosis);~* Known brain metastases;~* Uncontrolled hypertension;~* Recent treatment with chemotherapy, surgery or radiotherapy;~* Prior treatment with VEGF or VEGFR inhibitor.~The above information is not intended to contain all considerations relevant to participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study.
- Aflibercept (Type: EXPERIMENTAL): Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy child of 4 to 7 years of age of either gender,~* Child vaccinated with 2 doses of HEXAVAC® during the first 6 months of life and with a 3rd dose of HEXAVAC® before the end of the second year of life or Child vaccinated with 2 doses of INFANRIX®-HEXA during the first 6 months of life and with a 3rd dose of INFANRIX®-HEXA before the end of the second year of life,~* Informed consent form signed by the parent(s) or by the legal representative.~* Parent(s) or legal representative able to understand and comply with the study procedures.~Exclusion Criteria:~* Any recent (\<=3 days) history of febrile illness prior to vaccination,~* Receipt of more than 3 doses of any Hepatitis B containing vaccine, either alone or in any combination,~* History of clinical or serological-confirmed diagnosis of infection due to hepatitis B,~* History or current close contact with known carriers of hepatitis B virus,~* Prior known sensitivity/allergy to any component of the study vaccines,~* Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems,~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~* Any immune impairment or humoral/cellular deficiency or depressed immunity,~* Any recent (\<=30 days) long-term (\>=14 days) administration of systemic corticosteroids given daily or on alternate days at \>=20 mg/day prednisone equivalent or scheduled administration through Visit 2,~* Any receipt (\<=3 months) of immunoglobulins or blood-derived products, or scheduled administration through Visit 2,~* Any recent (\<=14 days) receipt of an inactivated vaccine or scheduled administration through Visit 2,~* Any recent (\<=28 days) receipt of a live vaccine or scheduled administration through Visit 2

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Levocetirizine and Fexofenadine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese origin, will be recruited for this study~Exclusion Criteria:~* None of the subjects will have taken oral antihistamines, antidepressants, antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin for 2 weeks prior to testing.~* No subject shall perform physical exercise for 4 hours prior to the skin prick testing.~* Especially, Bronchial asthma, anaphylactic reactions in the history, use of beta-blockers, skin diseases in the test field are exclusion criteria.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo per os at time 0 hours + placebo per os at 12 hours.
- Levocetirizin (Type: ACTIVE_COMPARATOR): Levocetirizin 5mg at time 0 and placebo per os at 12 hours
- Fexofenadine (Type: ACTIVE_COMPARATOR): Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* If of reproductive potential, must agree to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control for the duration of the study~* Diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH)~* Have been treated with an optimal dose of statin for at least 6 weeks~Exclusion Criteria:~* Received treatment with low-density lipoprotein (LDL) apheresis within 4 weeks of screening or expect to undergo treatment with LDL apheresis during the course of the study~* Homozygous familial hypercholesterolemia~* Severe chronic heart failure~* Uncontrolled hypertension~* Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), unstable angina, or stroke within 3 months~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins~* Active or chronic hepatobiliary, hepatic, or gall bladder disease~* Pregnant or breast-feeding, or plans to become pregnant during the study or within 2 years after stopping study medication~* History of ileal bypass, gastric bypass, or other significant condition associated with malabsorption~* Human immunodeficiency virus (HIV) positive~* History of malignancy ≤5 years~* Donated blood products or has had phlebotomy of \>300 mL within 8 weeks or intends to donate 250 mL of blood products or receive blood products within the projected duration of the study~* Currently taking medications that are potent inhibitors or inducers of cytochrome P450 3A4 (CYP3A) (including but not limited to cyclosporine, systemic itraconazole or ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's wort) or has discontinued treatment \<3 weeks prior~* Consumes more than 2 alcoholic drinks per day~* Currently participating or has participated in a study with an investigational compound or device within 3 months~* Receiving treatment with systemic corticosteroids or taking systemic anabolic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib (Type: EXPERIMENTAL): Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete